Literature DB >> 31738894

SK channel activation potentiates auranofin-induced cell death in glio- and neuroblastoma cells.

Inge E Krabbendam1, Birgit Honrath2, Laura Bothof2, Eduardo Silva-Pavez3, Hernán Huerta3, Natalia M Peñaranda Fajardo4, Frank Dekker5, Martina Schmidt2, Carsten Culmsee6, Julio César Cárdenas7, Frank Kruyt4, Amalia M Dolga8.   

Abstract

Brain tumours are among the deadliest tumours being highly resistant to currently available therapies. The proliferative behaviour of gliomas is strongly influenced by ion channel activity. Small-conductance calcium-activated potassium (SK/KCa) channels are a family of ion channels that are associated with cell proliferation and cell survival. A combined treatment of classical anti-cancer agents and pharmacological SK channel modulators has not been addressed yet. We used the gold-derivative auranofin to induce cancer cell death by targeting thioredoxin reductases in combination with CyPPA to activate SK channels in neuro- and glioblastoma cells. Combined treatment with auranofin and CyPPA induced massive mitochondrial damage and potentiated auranofin-induced toxicity in neuroblastoma cells in vitro. In particular, mitochondrial integrity, respiration and associated energy generation were impaired. These findings were recapitulated in patient-derived glioblastoma neurospheres yet not observed in non-cancerous HT22 cells. Taken together, integrating auranofin and SK channel openers to affect mitochondrial health was identified as a promising strategy to increase the effectiveness of anti-cancer agents and potentially overcome resistance.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31738894     DOI: 10.1016/j.bcp.2019.113714

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  4 in total

1.  MYCN-Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc-/Glutathione Axis.

Authors:  Konstantinos V Floros; JinYang Cai; Sheeba Jacob; Richard Kurupi; Carter K Fairchild; Mayuri Shende; Colin M Coon; Krista M Powell; Benjamin R Belvin; Bin Hu; Madhavi Puchalapalli; Sivapriya Ramamoorthy; Kimberly Swift; Janina P Lewis; Mikhail G Dozmorov; John Glod; Jennifer E Koblinski; Sosipatros A Boikos; Anthony C Faber
Journal:  Cancer Res       Date:  2021-01-22       Impact factor: 13.312

2.  Pharmacological Inhibition of Epac1 Averts Ferroptosis Cell Death by Preserving Mitochondrial Integrity.

Authors:  Nshunge Musheshe; Asmaa Oun; Angélica María Sabogal-Guáqueta; Marina Trombetta-Lima; Sarah C Mitchel; Ahmed Adzemovic; Oliver Speek; Francesca Morra; Christina H J T van der Veen; Frank Lezoualc'h; Xiaodong Cheng; Martina Schmidt; Amalia M Dolga
Journal:  Antioxidants (Basel)       Date:  2022-02-04

Review 3.  The gold complex auranofin: new perspectives for cancer therapy.

Authors:  Farah H Abdalbari; Carlos M Telleria
Journal:  Discov Oncol       Date:  2021-10-20

4.  Targeting the splicing factor NONO inhibits GBM progression through GPX1 intron retention.

Authors:  Xu Wang; Mingzhi Han; Shuai Wang; Yanfei Sun; Wenbo Zhao; Zhiyi Xue; Xiangjun Liang; Bin Huang; Gang Li; Anjing Chen; Xingang Li; Jian Wang
Journal:  Theranostics       Date:  2022-07-11       Impact factor: 11.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.